Immunotherapy boosts standard treatment for aggressive cervical cancer
NCT ID NCT03738228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested whether adding the immunotherapy drug atezolizumab before and during standard chemoradiation could help control advanced cervical cancer that has spread to lymph nodes. Forty participants received the combination to see if it activated the immune system more effectively. The goal was to improve disease control, not to cure the cancer, as ongoing management is still needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University Medical Center
Augusta, Georgia, 30912, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
Women and Infants Hospital
Providence, Rhode Island, 02905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Timing matters: early platelet booster may prevent dangerous drops in cervical cancer treatment
- Can we predict who will benefit from immunotherapy? new study aims to find out.
- New drug cocktail targets Hard-to-Treat cancers
- Custom-Made cancer vaccine shows promise in advanced tumors
- New smart chemo targets tumors, spares healthy tissue